Stonepine Capital Management, LLC Scynexis Inc Transaction History

Stonepine Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.39 - $2.21 $1.75 Million - $2.78 Million	-1,259,549 Reduced 92.94%	95,637 $141 Million
Q4 2023 Feb 13, 2024	SELL	$1.56 - $2.24 $2.34 Million - $3.35 Million	-1,497,413 Reduced 52.49%	1,355,186 $3.02 Billion
Q3 2023 Nov 13, 2023	BUY	$1.93 - $3.64 $5.51 Million - $10.4 Million	2,852,599 New	2,852,599 $6.5 Billion
Q2 2023 Aug 11, 2023	BUY	$2.38 - $3.67 $5.94 Million - $9.16 Million	2,496,346 Added 554.74%	2,946,346 $8.69 Million
Q1 2023 May 12, 2023	BUY	$1.15 - $3.0 $517,499 - $1.35 Million	450,000 New	450,000 $1.35 Million
Q4 2021 Feb 14, 2022	SELL	$4.94 - $7.69 $31,255 - $48,654	-6,327 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.3 - $7.89 $33,003 - $49,131	6,227 Added 6227.0%	6,327 $34,000
Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $650 - $997	100 New	100 $1,000
Q1 2021 May 14, 2021	SELL	$6.93 - $9.63 $4.75 Million - $6.6 Million	-685,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.28 - $7.87 $2.93 Million - $5.39 Million	685,000 New	685,000 $5.24 Million

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $40.5M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.